China reduce some medicine price, every year more than 3 billion ...

?

The National Development and Reform Commission started in March 30th 2012 the first drug prices reduction, the industry is expected during the year will publish a series of prices of tightening measures, industry profits will continue in 2011 "incremental difficult growth" posture. Accordingly, medicine plate due to lack of momentum to continue in the adjustment period, some innovative, characteristics of listed companies will become investment "harbor of refuge".

?

Chinese officials decided since May 1st this year adjust part of the digestive system drugs maximum retail price. The move involved a total of 53 species, more than 300dosage forms specifications, by a reduce average of 17%, among them pharmaceutical price by a reduce average of 22%, expected annual lightening their burden about 3 billion Yuan.

In recent years China has been in the promotion of the health system reform, and actively carries out the drug price reform. Only in these two years, official has several times reduced drug prices, and strive to relieve people "expensive" problem.

?

But with the reform deepening, some institutional, structural contradiction of deep administrative levels begins to show, from all walks of life to the drug price issue also be more attention. National Development and Reform Commission the relevant responsible person said, they will continue to increase reform strength, research adapt to the reform requirements of the new situation of drug price management system, further improve the price formation mechanism.

?

Current, official used six aspects to strengthen and improve the relevant work. Including strengthening the cost and price survey and monitoring; improved drug pricing method, on the part of drug discovery uses the medicine economic evaluation and international price comparison approach to pricing, on the part of medicine explores uniform pricing; further increase of high drug price reduction efforts, especially to reduce foreign capital of drug price; coordination with the medicine production and circulation reform, focus on standardizing the drug circulation price behavior, promoting drugs circulation enterprise integration and optimization, to encourage the development of modern logistics industry; establishment of drug price dynamic adjustment mechanism, according to the cost of production and market price changes and other factors, timely adjustment of drug price; study of the implementation of price policy of encouraging pharmaceutical research and innovation, for has reached the international level of generics, in terms of price policy support.

?

The responsible person noted that, at present, China is the full implementation of the new version of GMP transformation and improvement project of national drug standards, each district should fully consider the medicine production enterprises to implement the new version of GMP transform and upgrade the quality of standard cost change, in the adjustment of drug price, appropriate grasp the price adjustment. For many of the production of generic drugs to the reference standard of quality advanced enterprise cost and market price to adjustment price ceiling. From the current perspective, by the price policy of small effect of three listed companies will become the market investment objectives, One is the enterprise with innovation ability, can be timely and effective to resolve the price reduction negative impact, two is the brand and the resource of traditional Chinese medicine enterprises, three is exclusive varieties or medical services enterprises.

dexter facebook timeline kim jong il kim jong il vaclav havel vaclav havel kim jong ii dead